Camelidae

Technological Innovations and Rising Pet Ownership Shape Future of Global Veterinary Diagnostic Equipment Market 2023 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 23, 2023

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Veterinary Diagnostic Equipment Market.

Key Points: 
  • The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Veterinary Diagnostic Equipment Market.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Veterinary Diagnostic Equipment Market during the forecast period?
  • What is the market share of the leading vendors in the Global Veterinary Diagnostic Equipment Market?
  • What modes and strategic moves are considered suitable for entering the Global Veterinary Diagnostic Equipment Market?

Confo Therapeutics’ Scientific Founder Jan Steyaert Receives Prestigious Gabbay Award for Contributions to Structural Biology

Retrieved on: 
Friday, October 28, 2022

Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.

Key Points: 
  • Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.
  • Professor Steyaert is the 24th scientist to receive the award and the first Belgian recipient.
  • We congratulate Jan on the award and the well-deserved recognition for his pioneering work, said Cedric Ververken, CEO of Confo Therapeutics.
  • Co-founded by Professor Steyaert, Confo Therapeutics utilizes the Confo technology which consists of single domain antibodies that transform unstable GPCRs into stable functional conformations, thereby facilitating drug discovery research for the creation of disruptive therapeutics.

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Retrieved on: 
Thursday, August 11, 2022

BRISBANE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.

Key Points: 
  • BRISBANE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.
  • We are building a strong portfolio of knowledge across GT Biopharmas TriKE product candidates through investigation of preclinical solid tumor and hematological cancers models.
  • Mr. Alan Urban a member of the Board of Directors has assumed the role of financial expert of the Audit Committee.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)

Retrieved on: 
Wednesday, July 20, 2022

Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.
  • This gives PRECIRIX priority access to Eckert & Ziegler's high-purity, non-carrier-added Actinium-225, which is used for the labeling of trial drugs in radionuclide therapy.
  • "Until now, clinical research and commercial use of Actinium-225 has been limited by the shortage of this radioisotope.
  • "We are particularly pleased to have an experienced radioisotope specialist like Eckert & Ziegler at our side to support our ambitious development plans."

Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix

Retrieved on: 
Wednesday, March 16, 2022

Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.

Key Points: 
  • Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
  • Paris, France, 16 March 2022 Jeito Capital (Jeito), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led an investment of 80 million in Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology.
  • Jeito has co-led this investment with INKEF Capital and Forbion, two other leading European Life Sciences funds.
  • Dr Rafale Tordjman, Founder and CEO at Jeito Capital, said: We are pleased to have co-led this financing in Precirix alongside other high-quality European investors.

 Elephas to Show First Data on Breakthrough Oncology Diagnostics Platform at American Association for Cancer Research

Retrieved on: 
Tuesday, March 8, 2022

Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the acceptance of three abstracts by the American Association for Cancer Research (AACR).

Key Points: 
  • Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the acceptance of three abstracts by the American Association for Cancer Research (AACR).
  • The Elephas mission is to change the view of cancer and get the right treatment regimens to patients more quickly.
  • With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients.
  • The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.